Barclays noted that the FDA indication for Regeneron (REGN) and Sanofi's (SNY) Praulent suggests that the drug is not approved for primary prevention in combination with a statin, which it believes will only cause more confusion for the path of Esperion (ESPR) ETC-1002 drug. The firm thinks the current value of Esperion reflects a peak market potential of well below $1B for ETC-1002, which the firm sees as "far too low" even in the settings set out for Praulent. Barclays has an Overweight rating and $150 price target on Esperion shares.

Reports business EPS of EUR 1.78, down 17.6% reported and 7.4% at CER. Reports Q1 IRFS net sales EUR 10.464B, up 2.4%. Paul Hudson, Chief Executive Officer, commented: "We are off to an excellent start in 2024, delivering on our strategic priorities and a transformation of our portfolio of medicines and vaccines to become a development-driven, tech-powered biopharma company committed to serving patients and accelerating growth. Continued strong performance by Dupixent and our new launches drove sales growth of seven percent. In parallel, we are delivering on our promise of increased investments in our late-stage pipeline to fully realize its value for patients and Sanofi. We are awaiting regulatory decisions for Dupixent in COPD, a progressive disease with limited effective treatment options. If approved, Dupixent will be the first biologic treatment in COPD. With the robust progress in our portfolio transformation, we reaffirm our financial guidance for 2024."